RARB antisense RNA 1 (RARB-AS1)

RARB antisense RNA 1 (RARB-AS1) is a long non-coding antisense RNA transcribed from the strand opposite the retinoic acid receptor beta (RARB) gene. Antisense RNAs such as RARB-AS1 can regulate the expression of their sense partner genes (in this case, RARB) at various levels, including transcription, mRNA stability, and translation, typically acting through RNA-RNA interactions, epigenetic modifications, or by recruiting chromatin-modifying proteins[1][3]. While antisense RNAs can play important roles in gene regulation and have broad effects on cellular function—especially through locus-specific effects—they are not considered classical therapeutic targets like receptors, enzymes, or ion channels[1][3]. No direct evidence was found that RARB-AS1 itself is a well-characterized therapeutic target, nor is there substantial literature documenting interaction with drugs, use as a biomarker, or direct disease association for this RNA, though regulation of the protein-coding RARB gene has clinical significance in cancer and development[4][5][7]. Some published information highlights the complexity of antisense lncRNA regulation but does not identify RARB-AS1 as a nominated therapeutic entity[1][3]. *Note: There is a substantial possibility that RARB-AS1 is either poorly characterized or conflated with broader information regarding the RARB gene or general antisense lncRNAs. No data directly supporting therapeutic targeting, drug interaction, or specific disease biomarker status for RARB-AS1 were found in the provided search results.*

Other names

RARB-AS1